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COVID-19 Vaccine: How did we get 
here so quickly?
Jane Kelly, MD 
Assistant State Epidemiologist 
Division of Acute Disease Epidemiology
How is it possible to develop and get a COVID-19 vaccine 
to market in record time? 
Developing COVID-19 vaccine in record time was 
possible because of some unprecedented events 
related to an earlier disease from more than 15 years 
ago – SARS. The SARS outbreak in 2003 prompted 
work on vaccine development that was abandoned 
when the disease was contained. The COVID-19 vaccine 
developers had that prior work upon which to build.  
By January 10, 2020, the SARS-CoV-2 (responsible for 
COVID-19) genome had been sequenced and released 
publicly. On January 11, scientists around the world 
began using that genetic information to create multiple 
vaccine approaches for COVID-19. Critically, the 
timetable for vaccine development was shortened for 
“business case” reasons.  
According to the New York Times, the longest periods 
in a typical vaccine development timeline belong to 
the Preclinical, Building factories, and Manufacturing 
phases, and none of the phases overlap (Thompson, 
2020). Unlike this usual timeline and because of the 
federal government’s commitment to purchasing vaccine, 
companies did not have to proceed sequentially to ensure 
return on investment. In the COVID-19 vaccine timeline, 
Academic Research and Preclinical had a head start from 
previous SARS work and the published genome; Phases 
I, II, and III trials had some overlap; and Building factories 
and Manufacturing phases began early on. 
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No steps have been skipped in COVID-19 vaccine 
development in the United States but instead have 
overlapped. Vaccine development acceleration can be 
done without sacrificing efficacy and short-term safety. 
Long-term immunity persistence and safety evaluation 
must continue.
Reference: 
Thompson, S. A. How long will a vaccine really take? The New York 
Times, April 30, 2020. Accessed November 8, 2020 from: https://www.
nytimes.com/interactive/2020/04/30/opinion/coronavirus-covid-
vaccine.html
Historical Perspective on  
Vaccine Hesitancy
Jane Kelly, MD 
Assistant State Epidemiologist 
Division of Acute Disease Epidemiology
The era of COVID-19 offers a new twist to vaccine 
hesitancy. Even persons with confidence in the emergency 
use authorization (EUA) approval process assuring safety 
and at least 50% efficacy for upcoming vaccines are 
asking: “Would I recommend taking the first vaccine 
available or wait to see if a more efficacious one comes 
out?” This isn’t the first time this scenario has come up in 
US history. 
After World War II, as more Americans moved to crowded 
urban settings, and, ironically, hygiene improved such that 
children were not exposed to polio at a young age when 
they were less likely to be symptomatic, polio incidence 
began to rise (Table 1). By peak year 1952, there were 
more than 58,000 cases, 21,000 permanently paralyzed, 
and 3,000 dead. Two vaccines, inactivated polio 
vaccine (IPV) and oral polio vaccine (OPV) were under 
development, but clinical trials for IPV were completed by 
1954. Some scientists argued that OPV would offer better 
protection in preventing infection and recommended 
postponing mass vaccination until trials were completed 
(likely a two-year wait). Americans would not hear of it. 
People were clamoring for a vaccine. Three thousand dead 
and 21,000 paralyzed in one year was intolerable.
Mass vaccination with the IPV began in 1955, and annual 
cases decreased successively to 30,000 (1955), then 
15,000 (1956) and 7,000 (1957).  The urgency of the 
polio public health crisis dictated using the first vaccine 
available known to be safe and efficacious, even though 
some thought OPV, when eventually offered, would be 
better.
We are in a comparable 
situation qualitatively in 
that it is likely more than 
one COVID-19 vaccine 
will be given EUA status, 
though some earlier than 
others. Should we wait to 
see which one is best? 
Would you recommend 
waiting six months to see if 
a later vaccine might prove 
more efficacious in the 
elderly before vaccinating 
nursing home residents? 
People clamored for a vaccine in 1955 because the 
number of cases and deaths were compelling. Contrast 
these numbers with COVID-19 (Table 2). The case 
rate for COVID-19 are more than 210 times higher and 
deaths/100,00 more than 160 times higher as of this 
writing in February 2021 than polio was in 1952.  
 
The FDA has assured any vaccine application for EUA will 
undergo rigorous scrutiny to assure safety and efficacy. 
COVID-19 has killed more than 10 times as many people 
in 2020 than influenza has annually the past several years. 
As public health professionals, we weigh risks and benefits 
and provide clear information to the public. Comparison to 
historical experiences offer a sobering perspective 
References:
1. Centers for Disease Control and Prevention. COVID-19 Tracker. 
https://covid.cdc.gov/covid-data-tracker/#cases_casesper100k. 
Accessed November 8, 2020
2. Oshinsky, DM. Polio: An American Story. Oxford University Press, 
New York, NY. 2006
New mRNA Vaccine Technology
Jane Kelly, MD 
Assistant State Epidemiologist 
Division of Acute Disease Epidemiology
At this time, it seems likely that one or both mRNA 
vaccines (made by Pfizer and Moderna) will be the first 
ones available. These vaccines use a novel platform of 
delivery. Rather than inactivated or attenuated whole virus, 
or antigen vaccines presenting protein subunit with or 
without a vector, the mRNA vaccines deliver a segment 
of genetic code containing the directions for making the 
spike protein (which is the virus’s attachment site to enter 
the cell). The vaccine delivers the mRNA instructions, the 
cells make spike protein, which is released and induces 
antibody production and memory T cell activation to 
the spike protein. Ideally, this dual response of B and T 
cells will provide a robust response when an individual is 
exposed to SARS-CoV-2.
There are, however, lots of logistical challenges. Both 
vaccines require two doses (separated by 21 and 28 days 
for the Moderna and Pfizer vaccines, respectively) and 
the booster dose must be consistent with the first vaccine 
administered. Cold-chain considerations will impact 
vaccine distribution as the Pfizer vaccine needs to be held 
in storage of -94℉ and the Moderna vaccine at -40℉.  
Although no serious adverse events have been noted in 
Phase 1-3 trials involving more than 60,000 participants, 
mRNA vaccine is a new technology and rare events may 
only arise after many thousands more are vaccinated.
References:
1. Collins, Francis. NIG Director’s blog. July 16, 2020 https://
directorsblog.nih.gov/2020/07/16/researchers-publish-encouraging-
early-data-on-covid-19-vaccine/ 
Table 1.  
Polio Incidence, US 





Table 2.  
Polio vs. COVID-19: Cases, Case Rates, and Deaths






Polio 1952 58,000 37 3,000
COVID-19 2/2020- 
2/2021 
27,669,556* 8,334*  489,067* 
 *As of 2/18/2021, CDC
Laboratory Criteria of the Spotted 
Fever Rickettsiosis and Lyme 
Disease Case Definitions 
Christina Paul, MPH, CPH 
Vector-Borne Disease Epidemiologist 
Division of Acute Disease Epidemiology
Spotted Fever Rickettsiosis (SFR) and Lyme disease are 
the two most commonly reported tick-borne diseases in 
South Carolina. SFR includes cases of Rocky Mountain 
Spotted Fever (Rickettsia rickettsii), Rickettsia parkeri 
rickettsiosis, Pacific Coast Tick Fever (Rickettsia species 
364D) and other rickettsial species. Between 2006 and 
2018, 20 to 95 cases of SFR were reported annually in the 
state (Division of Acute Disease Epidemiology [DADE], 
2019). Between 2006 and 2018, 22 to 77 cases of Lyme 
disease were reported annually in the state (DADE, 
2019).  This summary provides information regarding the 
laboratory criteria used for public health surveillance in the 
SFR and Lyme disease case definitions, including recent 
updates to these criteria. 
 
Spotted Fever Rickettsiosis (SFR)
The SFR case definition was updated in 2020 and includes 
the following changes to the laboratory criteria:
• IgM serology test results are no longer included as 
part of the laboratory criteria. Previously, positive 
IgM results by indirect immunofluorescence antibody 
assays (IFA) were listed as part of the Supportive 
Laboratory Evidence. However, this has been removed 
as IgM results may be less specific than IgG results for 
diagnosing a recent infection (CDC, 2018). 
• A category for Presumptive Laboratory Evidence was 
added to the case definition. This category includes 
positive IgG serology results >1:128 by IFA. 
• The Supportive Laboratory Evidence was amended to 
include positive IgG serology results <1:128 by IFA.
• Both the Presumptive and Supportive Laboratory 
Evidence now include a criterion that positive 
specimens must be collected within 60 days of the 
patient’s illness onset date to be used for surveillance 
purposes (CDC, 2020). 
Image credit: NIH 
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The specific categories of the current SFR case definition 
are listed below:
Supportive Laboratory Evidence
• Serologic evidence of elevated IgG antibody at a titer 
<1:128 reactive with Spotted fever group Rickettsia 
(SFGR) antigen by IFA in a sample taken within 60 
days of illness onset.
Presumptive Laboratory Evidence
• Serologic evidence of elevated IgG antibody at a titer 
≥1:128 reactive with SFGR antigen by IFA in a sample 
taken within 60 days of illness onset. 
Confirmatory Laboratory Evidence
• Detection of SFGR nucleic acid in a clinical specimen 
via amplification of a Rickettsia genus- or species-
specific target by Polymerase Chain Reaction (PCR) 
assay OR
• Serological evidence of a fourfold increase in IgG-
specific antibody titer reactive with SFGR antigen by 
indirect IFA between paired serum specimens (one 
taken in the first two weeks after illness onset and 
a second taken 2 to 10 weeks after acute specimen 
collection) OR
• Demonstration of SFGR antigen in a biopsy or autopsy 
specimen by immunohistochemical methods (IHC) OR
• Isolation of SFGR from a clinical specimen in cell 
culture and molecular confirmation (e.g., PCR or 
sequence).
The Case Classifications (Confirmed, Probable, Suspect) 
for SFR were also revised to reflect the changes in the 
laboratory criteria. The full SFR case definition, including 




The current version of the Lyme disease case definition 
(dated 2017) includes the following criteria for laboratory 
results for the purposes of public health surveillance. 
Patients having any of these criteria would be considered 
to have laboratory evidence of infection for Lyme disease 
(CDC, 2017).
• A positive culture for Borrelia burgdorferi 
• A positive two-tiered test
 ▪ A positive two-tiered test is defined as a positive 
or equivocal enzyme immunoassay (EIA) or 
immunofluorescent assay (IFA) followed by a positive 
Immunoglobulin M (IgM) or Immunoglobulin G (IgG) 
western mmunoblot (WB) for Lyme Disease.
 ▪ An IgM WB is considered positive when at least two 
of the following three bands are present: 
 ▪ 24 kilodalton (kDa) outer surface protein C 
(OspC)*
 ▪ 39 kDa basic membrane protein A (BmpA)
 ▪ 41 kDa (Fla). 
• Additionally, the specimen of a positive IgM WB result 
must be collected within 30 days of the patient’s illness 
onset to be used for surveillance purposes.
• An IgG WB is considered positive when at least five of 
the following 10 bands are present: 
Parotitis Associated with Mumps 
and Other Viral Infections 
Clarissa A. Felima, MPH, CHES 
Vaccine Preventable Disease (VPD) Epidemiologist 
Division of Acute Disease Epidemiology
Parotitis, swelling in one or both parotid glands, has 
historically been associated with mumps viral infection. 
However, this symptom has also been reported in 
individuals who have tested positive for other viral 
infections, such as influenza and, now, COVID-19. 
• A positive single-tier IgG WB test for Lyme disease (see 
the details above regarding the band requirements to  
be considered a positive IgG WB)
 ▪ While a single IgG WB is adequate for surveillance 
purposes, a two-tier test is still recommended for 
patient diagnosis. 
*Depending upon the assay, OspC could be indicated by a band of 21, 
22, 23, 24 or 25 kDA.
 ▪ 18 kDa
 ▪ 24 kDa (OspC)*
 ▪ 28 kDa
 ▪ 30 kDa
 ▪ 39 kDa (BmpA)
 ▪ 41 kDa flagellin 
(Fla)
 ▪ 45 kDa
 ▪ 58 kDa (not GroEL)
 ▪ 66 kDa
 ▪ 93 kDa.
Information about reporting cases of SFR and Lyme 
disease to DHEC can be found on the DHEC List of 
Reportable Conditions, which is updated annually. This 
document can be found at: https://scdhec.gov/sites/
default/files/Library/CR-009025.pdf 
References:
1. Centers for Disease Control and Prevention. (2017). Lyme disease 
(Borrelia burgdorferi) 2017 case definition. https://wwwn.cdc.gov/
nndss/conditions/lyme-disease/case-definition/2017/
2. Centers for Disease Control and Prevention. (2018, October 26). 
Rocky mountain spotted fever (RMSF): Clinical and laboratory 
diagnosis. https://www.cdc.gov/rmsf/healthcare-providers/ClinLab-
Diagnosis.html
3. Centers for Disease Control and Prevention. (2020). Spotted fever 
rickettsiosis (including rocky mountain spotted fever) (SFR, including 
RMSF) 2020 case definition. https://wwwn.cdc.gov/nndss/conditions/
spotted-fever-rickettsiosis/case-definition/2020/
4. Division of Acute Disease Epidemiology. (2019). The South Carolina 
annual morbidity report on reportable conditions – 2018. Columbia, SC: 
South Carolina Department of Health and Environmental Control, Bureau 
of Communicable Disease Prevention and Control. https://scdhec.gov/
sites/default/files/Library/CR-012452.pdf
Image credit: CDC 
According to Dr. Mariel Marlow, CDC Epidemiologist on 
the Mumps, Varicella, and Zoster (MuVZ) Epidemiology 
Team, as of epi week 46 (November 14, 2020), 42 states 
had reported 592 mumps cases compared with 50 states 
and 3,323 mumps cases as of the same time in 2019. 
Mumps cases continued to be reported throughout the 
period of COVID lockdowns and other control measures, 
with 31 states reporting 107 cases from April 2020 through 
November 14, 2020. Because of this, clinical evaluation of 
patients with parotitis and consideration of mumps and 
other viral testing in these patients remain important for 
clinical and public health management.  
COVID-19 and Parotitis Case Reports
A case report in the American Journal of Emergency 
Medicine described a 21-year-old woman who was 
diagnosed with COVID-19-associated parotitis (Fisher et 
al, 2020). The patient was not tested for mumps but tested 
positive for COVID-19 upon evaluation at an emergency 
department. A study published in Emerging Infectious 
Diseases reported three patients in France who presented 
with parotitis-like symptoms as a clinical manifestation 
of confirmed COVID-19 infection (Lechien et al., 2020). 
Although the three cases were not tested for mumps, they 
were fully vaccinated for mumps. All three patients were 
female, ranging in age from 23 years to 31 years, and all 
were identified in a short period of time, with illness onsets 
ranging from March 21, 2020, to April 2, 2020. The patients 
also exhibited other symptoms consistent with COVID-19 
such as loss of smell and taste, myalgia, and headache. 
Mumps and Other Viral Testing
Based on these reports, it remains important to test 
for mumps in patients presenting with parotitis, while 
also considering other diagnostic testing. Testing for 
influenza should be considered if influenza is known to be 
circulating in the community. And testing for COVID-19 
may also be appropriate, especially if patients present 
with other symptoms consistent with this condition. 
Additionally, mumps should not be ruled out based on 
patients’ age or vaccination status. Most mumps cases in 
the US are now adults and fully vaccinated (Marlow, 2020). 
Therefore, patients with these characteristics who present 
with parotitis should still be tested for mumps. 
To test patients for mumps, collect buccal swab 
specimens for RT-PCR testing as soon as mumps 
infection is suspected. RT-PCR has the greatest diagnostic 
sensitivity when samples are collected within three days of 
symptom onset. The buccal swab specimens are obtained 
by massaging the parotid gland area for 30 seconds prior 
to swabbing the area around Stensen’s duct. If it has 
been greater than three days since symptom onset, it is 
still recommended to collect: 1) a buccal swab specimen 
for RT-PCR testing; and 2)  7–10 mL of blood in a red-
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Updates to the List of Reportable 
Conditions for 2021
Tashauna Lane 
Data Security Officer/Surveillance System Trainer 
Division of Acute Disease Epidemiology
Abdoulaye Diedhiou, MD, MS, PhD 
Director  
Division of Acute Disease Epidemiology
South Carolina Law 44-29-10 and Regulation 61-20 
require reporting of conditions on the Official List of 
Reportable Conditions in the manner prescribed by DHEC. 
South Carolina Law 44-53-1380 requires reporting by 
laboratories of all blood lead values in children under 6 
years of age. Changes to the LORC for 2021 are listed 
below.
Conditions Added
• Coronavirus Disease 2019 (COVID-19), has been added 
to urgently reportable within 24 hours by phone and the 
following footnote included.
 ▪ Footnote 17: COVID-19 cases, deaths, and 
multisystem inflammatory syndrome in children are 
urgently reportable within 24 hours. All COVID-19 
test results, including positives, negatives and 
indeterminates, are required to be reported. For 
detailed information about reporting COVID-19 test 
results, please go to: http://www.scdhec.gov/sites/
default/files/Library/CR-012859.pdf
• HIV-exposed infants, has been added to reportable 
within three business days.
• HIV 1/2 AB/AG+ and/or detectable viral load with each 




For all suspected and confirmed cases, report the 
following:
• Patient’s complete name (first, middle and last) 
• Patient’s complete address, phone number, county, 
date of birth, race, sex, last five digits of social security 
number
• Physician’s name and phone number
• Name, institution, and phone number of person 
reporting 
• Disease or condition 
• Date of diagnosis 
• Symptoms
• Date of onset of symptoms
• Lab results, specimen site, collection date
• If female, pregnancy status 
• Patient status: in childcare, food-handler, healthcare 
worker, childcare worker, in nursing home, prisoner/
detainee, travel in last four weeks
2. How to report
The “How to Report” section of the LORC has been 
updated to reflect changes in the mailing address for 
reporting HIV, AIDS, STDs (excluding Hepatitis) and 
Lead, and the contact information to establish electronic 
reporting for Lead.
For HIV, AIDS, and STDs (excluding Hepatitis):
• Do not fax HIV, AIDS, or STD results to DHEC
• Call 1-800-277-0873; or
• Submit electronically via DHEC’s web-based reporting 
system; or
• Mail to: 
Division of Surveillance, Assessment & Evaluation 
Mills/Jarrett Complex 
2100 Bull St., Columbia, SC 29201
For Lead:
• Mail to: 
Bureau of Population Health Data, Analytics and 
Informatics, Lead Surveillance 
Sims-Aycock Building,  
2600 Bull St., Columbia, SC 29201
• Fax: (803) 898-3236; or 
• Email: scionlead@dhec.sc.gov to establish electronic 
reporting
The “How to Report Other Conditions” section has been 
updated to reflect the change in the fax numbers for the 
Pee Dee region (Chesterfield, Clarendon, Darlington, 
Florence, Lee, Marlboro, Sumter, Williamsburg). The only 
fax number to use is (843) 915-6506.
As a reminder, all conditions other than HIV, AIDS, STDs, 
Lead and TB must be reported to the public health office 
in the region in which the patient resides. Immediately 
and urgently reportable conditions must be reported 
by telephone (for specific information about reporting 
COVID-19, go to: https://scdhec.gov/sites/default/files/
Library/CR-009025.pdf Conditions which are routinely 
reportable must be reported via mail, fax or submitted 
electronically via DHEC’s web-based reporting system.
Resources for Additional Information
• Reportable Diseases Page on DHEC website  
https://scdhec.gov/health-professionals/south-
carolina-list-reportable-conditions
• PDF List of Reportable Conditions 
https://scdhec.gov/sites/default/files/Library/CR-
009025.pdf
• SC DHEC Disease Reporting Form https://scdhec.gov/
sites/default/files/Library/D-1129.pdf
Questions?
For questions about Disease Reporting or to discuss 
electronic disease reporting via DHEC’s electronic disease 
surveillance reporting system, call the Division of Acute 
Disease Epidemiology in Columbia: (803) 898-0861 (M-F 
8:30 a.m. to 5 p.m.). To learn about DHEC’s web-based 
reporting system, call 1-800-917-2093 (M-F 8:30 a.m. to 5 
p.m.).
top or serum-separator tube (SST) for IgM detection. If 
assistance with mumps testing is needed, please contact 
the regional health department in your area. Contact 




1. J. Fisher, D.L. Monette, K.R. Patel, et al. (2020). COVID-19 associated 
parotitis: A case report, American Journal of Emergency Medicine, 
https://doi.org/10.1016/j.ajem.2020.06.059 
2.Lechien, J. R., Chetrit, A., Chekkoury-Idrissi, Y., Distinguin, L., Circiu, 
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interview].
Sources:
1.  Centers of Disease Control and Prevention (CDC), Mumps Job-Aid 
Template for Providers: https://www.cdc.gov/mumps/health-
departments/provider-job-aid.html
2. Centers of Disease Control and Prevention (CDC), Influenza & 
Parotitis: Question & Answers for Health Care Providers: https://www.
cdc.gov/flu/about/season/questions-answers-parotitis.htm
3. Centers of Disease Control and Prevention (CDC), Specimen 
Collection, Storage, and Shipment: https://www.cdc.gov/mumps/lab/
specimen-collect.html
South Carolina 2021 List of Reportable Conditions
(L)  Only Labs required to report. 
1. An outbreak is the occurrence of more cases of disease than normally expected within 
a specific place or group of people over a given period of time. Clinical specimens may 
be required.
2. Include drug susceptibility profile.
3. Invasive disease = isolated from normally sterile site. Always specify site of isolate.
4. Report Gram-negative diplococci in blood or CSF.
5. Specimen submission to the Public Health Laboratory (PHL) is required. Ship 
immediately and urgently reportables within 1 business day. Ship 3 day reportables 
within 3 business days. Contact regional staff if assistance is needed.
6. Rabies exposure prophylaxis guidance: www.scdhec.gov/health-professionals/clinical-
guidance-resources/rabies-treatment/rabies-guide-managing-exposures#contacts. 
Consultation is available from DHEC Regional Public Health Office.
7. Report aggregate totals weekly.
8. Report all cases of suspect and confirmed tuberculosis (TB). A suspect case of TB is 
a person whom a health care provider suspects TB based on signs, symptoms, and/or 
laboratory evidence of TB. Centers for Disease Control and Prevention case definition 
of confirmed cases: https://wwwn.cdc.gov/nndss/conditions/tuberculosis.
9. Carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii from all 
specimen types.
10. Appropriate specimen types: A pure, low passage isolate  submitted on a  
noninhibitory, non-selective agar plate or slant is preferred. If available submit one 
original culture plate.
11. Specimen submission to the PHL is required for Streptococcus pneumoniae, invasive 
in cases < 5 years of age.
12. Specimen submission of the first isolate of the month to the PHL is required for 
Carbapenem-resistant Pseudomonas aeruginosa.
13. All blood lead results are reportable within 30 days. Any elevated results (5 mcg/dL or 
greater) are reportable within 7 days.
14. Positive IGRAs alone do not diagnose TB disease versus Latent TB Infection (LTBI). 
www.scdhec.gov/sites/default/files/media/document/Memo%2010.2.19%20on%20
list%20of%20reportable%20conditions.pdf
15. Send all yeast isolates from any source to PHL except, C. albicans, C. krusei, C. 
dubliniensis, C. lusitaniae, C. parapsilosis, C. tropicalis
16. Negative results are reportable for Hepatitis B, C and Influenza only for laboratories 
that report via Electronic Laboratory Reporting (ELR).
17. COVID-19 cases, deaths, and multisystem inflammatory syndrome in children are 
urgently reportable within 24 hours. All COVID-19 test results, including positives 
and negatives, are required to be reported. For detailed information about reporting 
COVID-19 positive and negative results, please go to: www.scdhec.gov/sites/default/
files/Library/CR-012859.pdf
!  Any case that may be caused by chemical, biological, or 
radiological threat, novel infectious agent, or any cluster of cases, 
or outbreak of a disease or condition that might pose a substantial 
risk of human morbidity or mortality (1) (5) 
* Animal (mammal) bites (6)
! Anthrax (Bacillus anthracis) (5)
 Babesiosis (Babesia spp.)
! Botulism (Clostridium botulinum or Botulinum toxin)
* Brucellosis (Brucella spp.) (5)
 Campylobacteriosis (5)
* Candida auris or suspected (5) (15)
 Carbapenem-resistant Enterobacteriaceae (CRE) and Acinetobacter   
     baumanii (CRAB) (2) (5) (9)
 Carbapenem-resistant Pseudomonas aeruginosa (CRPA) (2) (5) (12) 




* Coronavirus Disease 2019 (COVID-19) (17)
 Creutzfeldt-Jakob Disease (Age < 55 years only)
 Cryptosporidiosis (Cryptosporidium spp.)
 Cyclosporiasis (Cyclospora cayetanensis) (5)
* Dengue (5)
* Diphtheria (Corynebacterium diphtheriae) (5)
* Eastern Equine Encephalitis (EEE) (5)
 Ehrlichiosis / Anaplasmosis (Ehrlichia / Anaplasma phagocytophilum)
* Escherichia coli, Shiga toxin – producing (STEC) (5)
 Giardiasis (Giardia spp.)
 Gonorrhea (Neisseria gonorrhoeae) (2)
* Haemophilus influenzae, all types, invasive disease (H flu) (2) (3) (5)
* Hantavirus
* Hemolytic uremic syndrome (HUS), post-diarrheal
* Hepatitis (acute) A, B, C, D, & E (16)
 Hepatitis (chronic) B, C, & D (16)
 Hepatitis B surface antigen + with each pregnancy
 HIV and AIDS clinical diagnosis
 HIV CD4 test results (all results) (L)
 HIV exposed infants
 HIV subtype, genotype, and phenotype (L)
 HIV 1 or HIV 2 positive test results (detection and confirmatory tests) (L)
 HIV 1/2 AB/AG+ and/or detectable viral load with each pregnancy
 HIV viral load (all results) (L)
 HIV HLA-B5701 and co-receptor assay (L)
! Influenza, avian or other novel strain
* Influenza associated deaths (all ages)
 Influenza
• Lab-confirmed cases (eg. culture, RT-PCR, DFA, Molecular assay) (16)
• Influenza associated hospitalizations (7)
* La Crosse Encephalitis (LACV) (5)
 Lead tests, all results - indicate venous or capillary specimen (13)
 Legionellosis
 Leprosy (Mycobacterium leprae) (Hansen’s Disease)
 Leptospirosis
 Listeriosis (5)
 Lyme disease (Borrelia burgdorferi)
 Lymphogranuloma venereum
 Malaria (Plasmodium spp.)
! Measles (Rubeola)
! Meningococcal disease (Neisseria meningitidis) (2) (3) (4) (5)
* Mumps
* Pertussis (Bordetella pertussis)
! Plague (Yersinia pestis) (5)
! Poliomyelitis
 Psittacosis (Chlamydophila psittaci)
* Q fever (Coxiella burnetii)
! Rabies (human)
 Rabies Post Exposure Prophylaxis (PEP) when administered (6)
* Rubella (includes congenital)
 Salmonellosis (2) (5)
* Shiga toxin positive (5)
 Shigellosis (2) (5)
! Smallpox (Variola)
 Spotted Fever Rickettsiosis (Rickettsia spp.)
*  Staphylococcus aureus, vancomycin-resistant or intermediate with a   
 VA >6 MIC (VRSA/VISA) (2) (5) (10)
 Streptococcus group A, invasive disease (2) (3)
 Streptococcus pneumoniae, invasive (pneumococcal) (2) (3) (11)
* St. Louis Encephalitis (SLEV) (5)
*  Syphilis: congenital, primary, or secondary (lesion or rash) or Darkfield 
positive
 Syphilis: early latent, latent, tertiary, or positive serological test
 Tetanus (Clostridium tetani)
 Toxic Shock (specify staphylococcal or streptococcal)
* Tuberculosis (Mycobacterium tuberculosis) (5) (8) 
 Tuberculosis test - Positive Interferon Gamma Release Assays (IGRAs):  
 QuantiFERON-TB Gold Plus (QFT-Plus) and T-SPOT.TB (14) (L)
* Tularemia (Francisella tularensis) (5)
* Typhoid fever (Salmonella typhi) (2) (5)
* Typhus, epidemic (Rickettsia prowazekii)
 Varicella
* Vibrio, all types, including Vibrio cholerae O1 and O139 (5)
! Viral Hemorrhagic Fevers (Ebola, Lassa, Marburg viruses)
* West Nile Virus (5)
* Yellow Fever
 Yersiniosis (Yersinia, not pestis)
* Zika (5)
REPORT UPON RECOGNITION OF A SUSPECTED CASE, DIAGNOSIS, OR POSITIVE LABORATORY EVIDENCE (SEE “HOW TO REPORT” ON BACK)
Suspected means clinical suspicion and/or initial laboratory detection, isolation, identification, or presence of supportive laboratory results.
   Potential agent of bioterrorism
!   Immediately reportable by phone call to a live person at the regional public health office, 24/7
*   Urgently reportable within 24 hours by phone 
All other conditions except lead are reportable within 3 business days
Epi Notes is published by the South Carolina Department of Health and Environmental Control 
Bureau of Communicable Disease Prevention and Control. 
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